What is Cosentyx’s interleukin target?
Cosentyx (secukinumab) is an interleukin inhibitor. It blocks interleukin-17A (IL-17A), a pro-inflammatory signaling molecule involved in autoimmune inflammation. [1]
Which type of interleukin does Cosentyx bind to (IL-17A vs IL-17F)?
Cosentyx specifically targets IL-17A. Other interleukin pathways, including different IL-17 family members, are not Cosentyx’s direct target based on the drug’s mechanism of action as an IL-17A blocker. [1]
What conditions is Cosentyx used for?
Cosentyx is used to treat several inflammatory conditions driven by IL-17A signaling, including:
- Plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Pediatric plaque psoriasis (in appropriate age groups, where approved) [1]
How does blocking IL-17A change inflammation?
By inhibiting IL-17A, Cosentyx reduces inflammatory activity that contributes to symptoms such as skin inflammation and joint pain/swelling in conditions where IL-17A is implicated. [1]
Where can I verify patent/drug details for Cosentyx?
For ongoing drug/patent research and related commercial background, DrugPatentWatch tracks Cosentyx (secukinumab) information here: [2]
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125472
[2] https://www.drugpatentwatch.com/p/ (DrugPatentWatch Cosentyx/secukinumab page)